Translational Development Acquisition (TDAC) Other Accumulated Expenses (2024 - 2026)

Translational Development Acquisition's Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $136762.0 for Q1 2026.

• Quarterly Other Accumulated Expenses rose 509.92% year-over-year to $136762.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136762.0 (up 509.92% YoY) and the FY2025 annual result came in at $106762.0, up 5238.1% from the prior year.
• Other Accumulated Expenses was $136762.0 for Q1 2026 at Translational Development Acquisition, up from $106762.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $136762.0 in Q1 2026 and bottomed at $2000.0 in Q4 2024.
• A 3-year average of $65245.2 and a median of $61762.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses surged 5238.1% — and 2026, when it soared 509.92%.
• Translational Development Acquisition's Other Accumulated Expenses stood at $2000.0 in 2024, then jumped by 5238.1% to $106762.0 in 2025, then advanced by 28.1% to $136762.0 in 2026.
• Business Quant data shows TDAC's Other Accumulated Expenses at $136762.0 in Q1 2026, $106762.0 in Q4 2025, and $76762.0 in Q3 2025.